POAI - Predictive Oncology Inc Stock Price, Fair Value and News

1.71USD+0.03 (+1.79%)Delayed

Market Summary

USD1.71+0.03

Delayed

1.79%

POAI Stock Price

View Fullscreen

POAI RSI Chart

POAI Valuation

Market Cap

7.0M

Price/Earnings (Trailing)

-0.47

Price/Sales (Trailing)

3.58

EV/EBITDA

-0.08

Price/Free Cashflow

-0.52

POAI Price/Sales (Trailing)

POAI Profitability

EBT Margin

-1313.25%

Return on Equity

-364.63%

Return on Assets

-139.43%

Free Cashflow Yield

-191.51%

POAI Fundamentals

POAI Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

74.93%

Rev. Growth (Qtr)

25.26%

POAI Earnings

Earnings (TTM)

-14.8M

Earnings Growth (Yr)

-23.29%

Earnings Growth (Qtr)

-21.39%

Breaking Down POAI Revenue

Last 7 days

4.9%

Last 30 days

31.5%

Last 90 days

-47.4%

Trailing 12 Months

-45.4%

How does POAI drawdown profile look like?

POAI Financial Health

Current Ratio

1.45

POAI Investor Care

Shares Dilution (1Y)

2.41%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0M	0	0	0
2023	1.4M	1.5M	1.8M	1.8M
2022	1.5M	1.5M	1.6M	1.5M
2021	1.2M	1.4M	1.2M	1.4M
2020	1.5M	1.3M	1.3M	1.3M
2019	1.3M	1.2M	1.4M	1.4M
2018	891.3K	1.1M	1.3M	1.4M
2017	534.8K	556.2K	574.1K	654.8K
2016	600.0K	451.4K	500.2K	456.5K
2015	1.0M	948.3K	636.9K	654.4K
2014	399.1K	566.5K	855.9K	951.6K
2013	317.0K	442.9K	499.1K	479.7K
2012	119.3K	141.9K	173.2K	188.8K
2011	0	42.7K	69.7K	96.6K
2009	0	0	0	15.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Predictive Oncology Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 05, 2024	rao veena	acquired	-	-	3,268	-
Apr 05, 2024	hawryluk matthew	acquired	-	-	2,368	-
Apr 05, 2024	chung-welch nancy	acquired	-	-	2,353	-
Apr 05, 2024	nuzum charles lee sr	acquired	-	-	3,268	-
Apr 05, 2024	handley daniel e	acquired	-	-	2,353	-
Apr 05, 2024	st. clair gregory sr	acquired	-	-	3,268	-
Oct 02, 2023	hawryluk matthew	acquired	-	-	1,875	-
Oct 02, 2023	handley daniel e	acquired	-	-	1,875	-
Oct 02, 2023	st. clair gregory sr	acquired	-	-	1,875	-
Oct 02, 2023	rao veena	acquired	-	-	1,875	-

Which funds bought or sold POAI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	reduced	-17.82	-20,110	35,284	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	sold off	-100	-14.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	12.34	-1,017	6,846	-%
May 13, 2024	NATIONAL BANK OF CANADA /FI/	new	-	162	162	-%
May 13, 2024	RB Capital Management, LLC	sold off	-100	-68,547	-	-%
May 13, 2024	UBS Group AG	reduced	-50.64	-5,198	3,221	-%
May 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	added	0.3	-27,450	95,858	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	21.16	-3,000	44,000	-%
May 10, 2024	BlackRock Inc.	sold off	-100	-500	-	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	3.23	-20.00	82.00	-%

Are Funds Buying or Selling POAI?

Are funds buying POAI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own POAI

No. of Funds

Unveiling Predictive Oncology Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 11, 2022	intracoastal capital, llc	3.5%	2,383,464	SC 13G/A
Mar 01, 2021	intracoastal capital, llc	7.4%	3,476,948	SC 13G
Jan 05, 2021	sabby management, llc	4.99%	882,063	SC 13G/A
May 15, 2020	armistice capital, llc	4.99%	552,686	SC 13G
May 01, 2020	sabby management, llc	5.88%	483,509	SC 13G
May 01, 2020	schwartz carl i.	17.2%	1,751,649	SC 13D/A
Apr 01, 2020	armstrong r douglas phd	3.61%	212,811	SC 13D/A
Mar 26, 2020	keyser robert d jr	2.38%	134,655	SC 13D/A
Nov 04, 2019	oasis capital, llc	9.99%	10	SC 13G
Oct 16, 2019	keyser robert d jr	6.87%	2,164,320	SC 13D/A

Recent SEC filings of Predictive Oncology Inc

View All Filings

Date Filed	Form Type	Document
May 15, 2024	8-K	Current Report
May 14, 2024	10-Q	Quarterly Report
May 06, 2024	S-3	S-3
May 06, 2024	8-K	Current Report
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading
Apr 12, 2024	4	Insider Trading

Peers (Alternatives to Predictive Oncology Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.13%	32.26%	-0.09	0.28	5.77%	8.23%

Predictive Oncology Inc News

Latest updates

Predictive Oncology Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	25.3%	419,646	335,032	715,056	490,110	239,895	363,473	455,827	371,591	314,568	476,493	313,663	350,207	280,317	293,788	480,757	182,784	294,943	347,477	522,696	286,151	255,241
Gross Profit	166.7%	232,231	87,076	608,116	330,349	119,756	210,035	347,676	237,516	205,125	340,269	203,498	207,330	182,559	199,720	305,551	97,523	202,286	302,958	314,600	167,761	7,348
Operating Expenses	-64.3%	4,469,003	12,515,391	842,579	993,042	878,518	24,376,690	857,130	909,113	891,071	907,022	648,935	567,796	574,812	713,074	568,766	521,116	548,753	514,893	707,414	1,271,258	466,566
S&GA Expenses	97.0%	739,734	375,478	336,043	429,103	370,237	450,041	333,377	271,022	304,467	327,232	172,869	159,788	114,641	65,999	121,514	133,015	264,409	238,699	434,955	685,029	554,216
EBITDA Margin	8.9%	-12.79	-14.04	-13.72	-15.91	-17.13	-16.22	-11.72	-12.86	-12.57	-12.87	-19.76	-17.41	-19.88	-	-	-	-	-	-	-	-
Interest Expenses	-59.6%	1,737	4,296	9,608	-	-	67.00	2,315	450	989	-5,481	1,554	-	-	1,040	144,791	-	-	-	-	-	-
EBT Margin	9.2%	-13.13	-14.46	-14.23	-16.61	-17.99	-17.10	-12.55	-13.76	-13.97	-14.30	-20.91	-18.42	-20.91	-	-	-	-	-	-	-	-
Net Income	-21.4%	-4,218,843	-3,475,347	-3,163,450	-3,923,368	-3,421,802	-7,916,110	-4,059,484	-10,391,324	-3,370,715	-7,756,512	-5,438,017	-2,573,932	-3,888,713	-11,469,976	-6,307,726	-3,577,378	-4,529,317	-14,617,438	-4,008,512	1,465,104	-1,166,656
Net Income Margin	4.0%	-7.54	-7.86	-10.19	-12.47	-18.02	-17.10	-15.80	-18.26	-13.15	-13.84	-18.88	-17.25	-20.40	-	-	-	-	-	-	-	-
Free Cashflow	-11.2%	-3,419,053	-3,075,064	-3,108,918	-3,829,630	-3,452,130	-3,292,941	-2,836,350	-3,522,283	-3,139,095	-3,940,003	-3,041,471	-2,424,108	-3,713,776	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-26.5%	11.00	14.00	18.00	21.00	25.00	26.00	33.00	36.00	26.00	44.00	51.00	57.00	40.00	13.00	25.00	27.00	25.00	22.00	32.00	32.00	5.00
Current Assets	-34.9%	7.00	10.00	14.00	16.00	20.00	23.00	27.00	30.00	26.00	29.00	43.00	46.00	28.00	2.00	3.00	4.00	4.00	1.00	1.00	1.00	4.00
Cash Equivalents	-40.5%	5.00	9.00	12.00	15.00	19.00	22.00	25.00	28.00	25.00	28.00	42.00	45.00	27.00	1.00	2.00	3.00	3.00	0.00	0.00	0.00	1.00
Inventory	-10.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net PPE	-11.8%	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	4.00	4.00	4.00	4.00	4.00	2.00	1.00	2.00	2.00	2.00	0.00
Goodwill	-	-	-	-	-	-	-	-	-	7.00	7.00	-	3.00	3.00	3.00	13.00	16.00	16.00	16.00	24.00	24.00	24.00
Liabilities	6.5%	7.00	6.00	7.00	6.00	7.00	4.00	4.00	3.00	3.00	4.00	3.00	4.00	4.00	10.00	13.00	16.00	15.00	11.00	11.00	10.00	5.00
Current Liabilities	14.3%	5.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	9.00	12.00	15.00	12.00	11.00	11.00	9.00	5.00
Shareholder's Equity	-51.0%	4.00	8.00	12.00	15.00	19.00	22.00	30.00	34.00	37.00	40.00	48.00	53.00	36.00	3.00	12.00	12.00	10.00	11.00	21.00	22.00	0.00
Retained Earnings	-2.5%	-171	-167	-164	-161	-157	-153	-145	-141	-131	-128	-120	-114	-112	-108	-96.91	-90.61	-87.03	-82.50	-68.94	-64.94	-66.40
Additional Paid-In Capital	0.0%	176	176	176	176	176	176	175	175	168	168	167	167	147	111	109	102	97.00	94.00	90.00	87.00	66.00
Shares Outstanding	0%	4.00	4.00	4.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	19.00	-	-	-	32.00	-	-	-	86.00	-	-	-	32.00	-	-	-	20.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-10.8%	-3,416	-3,082	-3,105	-3,574	-3,427	-3,234	-2,708	-3,334	-3,093	-3,744	-2,937	-2,204	-3,322	-2,303	-3,232	-3,748	-2,972	-2,795	-1,891	-1,996	-2,048
Share Based Compensation	-37.7%	734*	1.00	-14.30	6.00	9.00	63.00	27.00	39.00	37.00	89.00	29.00	33.00	565	164	135	135	288	246	360	1,381	264
Cashflow From Investing	-141.6%	-3.03	7.00	-3.92	-259	-46.64	-63.60	-143	-188	-80.24	-9,787	-186	-240	-393	-141	-116	122	-32.51	-7.33	-10.84	44.00	-624
Cashflow From Financing	-0.9%	-112	-111	260	-	-	-23.63	-4.03	6,656	87.00	-37.49	15.00	20,027	30,336	649	2,429	3,963	5,911	2,855	1,931	898	3,636
Buy Backs	-100.0%	-	2.00	-	-	-	24.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

POAI Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Assets, Current [Abstract]
Cash	$ 5,197,235	$ 8,728,660
Accounts receivable	509,445	333,697
Inventories	441,718	494,374
Prepaid expense and other assets	412,925	521,700
Total current assets	6,561,323	10,078,431
Property and equipment, net	1,087,718	1,233,910
Intangibles, net	245,594	252,457
Lease right-of-use assets	2,582,456	2,728,355
Other long-term assets	124,096	124,096
Total assets	10,601,187	14,417,249
Current liabilities:
Accounts payable	1,729,126	1,342,027
Note payable	38,036	150,408
Accrued expenses and other liabilities	1,904,612	1,631,702
Derivative liability	367	1,376
Contract liabilities	304,320	308,091
Lease liability	540,200	517,427
Total current liabilities	4,516,661	3,951,031
Other long-term liabilities	3,507	5,459
Lease liability – net of current portion	2,027,348	2,188,979
Total liabilities	6,547,516	6,145,469
Commitments and Contingencies
Stockholders’ equity:
Common stock, $.01 par value, 200,000,000 shares authorized, 4,062,853 shares outstanding as of March 31, 2024, and December 31, 2023	40,629	40,629
Additional paid-in capital	175,992,976	175,992,242
Accumulated deficit	(171,980,726)	(167,761,883)
Total stockholders’ equity	4,053,671	8,271,780
Total liabilities and stockholders’ equity	10,601,187	14,417,249
Series B Convertible Preferred Stock [Member]
Stockholders’ equity:
Series B Convertible Preferred Stock, $.01 par value, 2,300,000 shares authorized, 79,246 shares outstanding as of March 31, 2024, and December 31, 2023	$ 792	$ 792

About Predictive Oncology Inc

Predictive Oncology Inc. operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples. It operates through four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment provides services that include the application of AI, collaboration projects, and clinical testing. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using a self-contained automated system that conducts self-interaction chromatography screens using additives and excipients included in protein formulations resulting in soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Eagan, Minnesota.

CEO	Mr. Raymond F. Vennare
WEBSITE	predictive-oncology.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	31

Predictive Oncology Inc Frequently Asked Questions

What is the ticker symbol for Predictive Oncology Inc? What does POAI stand for in stocks?

POAI is the stock ticker symbol of Predictive Oncology Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Predictive Oncology Inc (POAI)?

As of Fri May 17 2024, market cap of Predictive Oncology Inc is 7.01 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of POAI stock?

You can check POAI's fair value in chart for subscribers.

What is the fair value of POAI stock?

You can check POAI's fair value in chart for subscribers. The fair value of Predictive Oncology Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Predictive Oncology Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for POAI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Predictive Oncology Inc a good stock to buy?

The fair value guage provides a quick view whether POAI is over valued or under valued. Whether Predictive Oncology Inc is cheap or expensive depends on the assumptions which impact Predictive Oncology Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for POAI.

What is Predictive Oncology Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, POAI's PE ratio (Price to Earnings) is -0.47 and Price to Sales (PS) ratio is 3.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. POAI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Predictive Oncology Inc's stock?

In the past 10 years, Predictive Oncology Inc has provided -0.449 (multiply by 100 for percentage) rate of return.